EXHIBIT D

Case 1:04-md-01592-MLW



50 FREMONT STREET SAN FRANCISCO, CA 94105-2228 415,983,1000 F: 415,983,1200 MAILING ADDRESS: P. O. BOX 7880 SAN FRANCISCO, CA 94120-7880

FACSIMILE			Total Pages (ir	nctuding cover):
HOUSTON LONDON	Date:	September 15, 2004	Must Be Sent I	Ву:
LOS ANGELES NÉW YORK NORTHERN VIRGINIA ORANGE COUNTY SACRAMENTO SAN DIEGO SAN FRANCISCO SILICON VALLEY SINGAPORE STAMFORD SYDNEY TOKYO WASHINGTON DC Confidentiality Note: The documents accompanying this facsimile transmission may contain confidential information which is legally phylleged. The information is intended only for the use of the individual or unity named above. If you are not the intended recipient, or the person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution or use of any of the information contained in this transmission is stictly PROHIBITED. If you have received this transmission is error, please immediately notify us by telephone and mail the	To:	Donald R. Ware, Esq. Claire Laporte, Esq. Carla M. Levy, Esq.	Fax No:	(617) 832-7000
	Company:	Foley Hoag LLP	Phone No:	(617) 832-1000
	To:	Adrian M. Pruetz, Esq. Charles K. Verhoeven, Esq. Robert W. Stone, Esq.	Fax No:	(415) 875-6700
	Company:	Quinn Emanuel Urquhart Oliver & Hedges LLP	Phone No:	(415) 875-6600
	To:	Mark A. Pals, Esq. Marcus E. Scrnel, Esq.	Fax No:	(312) 861-2200
	Company:	Kirkland & Ellis	Phone No:	(312) 861-2000
	To:	Peter E. Gelhaar, Esq. Michael S. D'Orsi, Esq.	Fax No:	(617) 720-2880
	Сопрану:	Donnelly Conroy & Gelhaar	Phone No:	(617) 720-3554
	To:	Eileen M. Herlihy, Esq.	Fax No:	(617) 227-4400
	Company;	Palmer & Dodge, LLP	Phone No:	(617) 239-0100
		Steven A. Zalesin, Esq. Melissa Mandrgoc, Esq.	Fax No:	(212) 336-2222
	Company:	Parterson Belknap Webb & Tyler	Phone No:	(212) 336-2000
	To:	Leora Ben-Ami, Esq. Patricia A. Carson, Esq.	Fax No:	(212) 836-6565
	Company:	Kaye Scholer LLP	Phone No:	(212) 836-8000
original transmission to us. Thank you,				

if you have not properly received this fax, please call (416) 983-1000. Thank you.

Time Sent

_Batch ID: _

Operator:



SEPTEMBER 15, 2004 PAGE 2

FACSIMILE

LONDON				
LOS ANGELES NEW YORK NORTHERN VIRGINIA ORANGE COUNTY	To:	Robert S. Frank, Jr., Esq. Eric J. Marandett, Esq. Paul D. Popeo, Esq.	Fax No:	(617) 248-4000
SACRAMENTO SAN DIÉGO	Сопрапу:	Choate, Hall & Stewart	Phone No:	(617) 248-5000
SAN FRANCISCO SILICON VALLEY SINGAPORE	To:	Thomas F. Maffei, Esq. Scott McConchie, Esq.	Fax No:	(617) 542-0900
STAMFORD SYDNEY	Сотраву:	Griesinger, Tighe & Maffei	Phone No:	(617) 542-9900
ТОКУО	From:	Kirke M. Hasson	Phone No:	(415) 983-1077
WASHINGTON DC	User No:	03500	C/M No:	011571 0000001

..•

Confidentiality Note: The documents accompanying this facsimile transmission may contain confidential information which is legally privileged. The information is intended only for the use of the Individual or entity named above. If you are not the intended recipient, or the person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution or use of any of the information notesimental aid an amission is strictly PROHIBITED. If you have received this trensmission in error, please Immediately notify as by telephone and malt the original transmission to us. Thank you.



50 FREMONT STREET SAN FRANCISCO, CA 94105-2228 415.983.1000 F: 415.983.1200 MAILING ADDRESS: P. O. BOX 7880 SAN FRANCISCO, CA 94120-7880

September 15, 2004

Kirke M. Hasson Phone: 415.983.1077 kirke.hasson@pillsburywinthrop.com

VIA FACSIMILE

David I. Gindler, Esq. Irell & Manella LLP 1800 Avenue of the Stars, Suite 900 Los Angeles, CA 90067

Wayne M. Barsky, Esq. Gibson, Dunn & Crutcher LLP 2029 Century Park East Los Angeles, CA 90067-3026

Re: Amgen, Inc. v. Columbia University litigation, MDL-1592

Dear Counsel:

Thank you for David Gindler's letter today inviting additional clarification of the Covenant. Plaintiffs request further clarification of the Covenant in seven categories:

- 1. "any product currently made, used, offered for sale, sold, or imported, or any product that was made, used, offered for sale, sold, or imported" (Covenant), and "by way of example, Rituxan is a product currently made and sold by Genentech" (Letter, Sept. 10, 2004). Please confirm:
- (a) The Covenant extends not only to vials or lots that were manufactured by September 1, 2004, but also to vials or lots of the same product manufactured at any time in the future, and to the use and sale of such material.
- (b) The Covenant extends to all proteins now sold (rituximab, epoetin alfa, etanercept, etc.), not merely the brand name products marketed.
- (c) The Covenant extends to all proteins now sold, even if changes are later made in the process by which such a protein is manufactured.

Case 1:04-md-01592-MLW



David I. Gindler, Esq. Wayne M. Barsky, Esq. September 15, 2004 Page 2

- The Covenant extends to all proteins now sold, even if a new construct or new transformed cells are later created to express any such protein.
- The Covenant refers to "any product." The '275 patent refers to transformed cells (e.g., '275 patent, claim 1), constructs (e.g., '275 patent, claim 20) and methods (e.g., '275 patent, claim 14). Please confirm:
- The Covenant extends to all transformed cells made by September 1, 2004, whether or not amplification of DNA I or DNA II has occurred.
 - (b) The Covenant extends to all constructs made by September 1, 2004.
- The Covenant extends to all proteins expressed before September 1, 2004 using such transformed cell or construct or method.
- The Covenant extends to the continued production, use or sale after September 1, 2004, of such cells, constructs and proteins.
 - 3. "The issue of new products" (RT 9/9/04, 29:24). Please confirm:
- (a) The Covenant extends to the future manufacture, use, sale, etc. of anything a plaintiff had produced by September 1, 2004, such as a transformed cell, a construct, or a cell line that had been made by September 1, 2004, regardless of whether that thing had yet led to any commercially sold product.
- As an example, the Covenant extends to the future manufacture, use, sale, etc. of a protein that a plaintiff had made by September 1, 2004, or of a construct, transformed cell, or cell line expressing that protein, where the protein was in pre-clinical or clinical trials on that date.
 - 4. "prior to the date of this covenant" (Covenant).

Please confirm that, if a scientist at one of the plaintiffs creates for the first time after September 1, 2004, a construct or a cotransformed cell, such as a first cotransformation with a DNA I encoding for a particular protein, the Covenant extends to:

- (a) such construct or cotransformed cell.
- (b) methods using such construct or cotransformed cell.
- (c) a protein produced using such construct or cotransformed cell.

Sep-15-2004 04:12pm From-PILLSBURY-WINTHORP LLP

4159937996

T-317 P.005/008 F-930



David I. Gindler, Esq. Wayne M. Barsky, Esq. September 15, 2004 Page 3

- 5. "This covenant is limited to the '275 patent as it presently reads and does not apply to any other patent, whether related or unrelated to the '275 patent. Specifically, this covenant does not apply to any reissued or reexamined version of the '275 patent that may issue in the future or to any patent that may issue from United States Patent Application No. 08/477,159" (Covenant). "The Covenant applies to any claim of any reissued or reexamined version of the '275 patent that is the same as, or substantially identical to, a claim of the '275 patent as it currently reads" (Letter, Sept. 10, 2004). "The Covenant does not apply to any claim in any patent that may issue in the future based upon the pending '159 application, irrespective of whether plaintiffs contend that such claim is the same as, or substantially identical to, a claim of the '275 patent as it currently reads" (Id.). Please confirm:
- (a) The September 10, 2004 letter was a modification (not merely a "clarification") of the Covenant, in stating that "The Covenant applies to any claim of any reissued or reexamined version of the '275 patent that is the same as, or substantially identical to, a claim of the '275 patent as it currently reads."
- (b) The Covenant extends to any claim in any patent that may issue in the future based upon the pending '159 application, if that claim is actually (not merely "contended" to be) identical or substantially identical to a claim of the '275 patent as it currently reads.
- (c) Other than the '159 application and the '275 reissue, no pending patent applications exist that claim priority to U.S. Application Serial No. 06/124,513.
- 6. "The Covenant does not apply to [plaintiffs'] affiliates or customers" (Letter, Sept. 10, 2004). Please confirm that a plaintiff's rights under the Covenant are transferable by the plaintiff with the product. In other words, please confirm that the Covenant applies to a covered product if, for example, a plaintiff elects to have the product manufactured for it by an affiliate or third party, or sold by an affiliate or third party. Similarly, please confirm that the Covenant applies to a covered product if a plaintiff sells its business in the product to a third party.
- 7. Columbia "covenants... not to assert any claim of patent infringement" (Covenant). Please confirm that this extends to activity by a plaintiff that could be considered to be contributory infringement or inducement of infringement of the '275 patent.

4159837396

T-317 P.006/006 F-930



David I. Gindler, Esq. Wayne M. Barsky, Esq. September 15, 2004 Page 4

Plaintiffs would appreciate Columbia's written confirmation on these points as soon as possible tomorrow, and no later than 5:00 pm PST. If you would like to discuss these issues, please let us know when.

Very truly yours,

Kirke M. Hasson

cc: All plaintiffs' counsel